Literature DB >> 19602591

Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.

Johan Hartman1, Karin Edvardsson, Karolina Lindberg, Chunyan Zhao, Cecilia Williams, Anders Ström, Jan-Ake Gustafsson.   

Abstract

Estrogen receptor beta (ERbeta) is the predominant ER in the colorectal epithelium. Compared with normal colon tissue, ERbeta expression is reduced in colorectal cancer. Our hypothesis is that ERbeta inhibits proliferation of colon cancer cells. Hence, the aim of this study has been to investigate the molecular function of ERbeta in colon cancer cells, focusing on cell cycle regulation. SW480 colon cancer cells have been lentivirus transduced with ERbeta expression construct with or without mutated DNA-binding domain or an empty control vector. Expression of ERbeta resulted in inhibition of proliferation and G(1) phase cell cycle arrest and this effect was dependent on a functional DNA-binding region. c-Myc is overexpressed in an overwhelming majority of colorectal tumors. By Western blot and real-time PCR, we found c-Myc to be down-regulated in the ERbeta-expressing cells. Furthermore, the c-Myc target gene p21((Waf1/Cip1)) was induced and Cdc25A was reduced by ERbeta at the transcriptional level. The second cdk2-inhibitor, p27(Kip1), was induced by ERbeta, but this regulation occurred at the posttranscriptional level, probably through ERbeta-mediated repression of the F-box protein p45(Skp2). Expression of the ERbeta-variant with mutated DNA binding domain resulted in completely different cell cycle gene regulation. We performed in vivo studies with SW480 cells +/- ERbeta transplanted into severe combined immunodeficient/beige mice; after three weeks of ERbeta-expression, a 70% reduction of tumor volume was seen. Our results show that ERbeta inhibits proliferation as well as colon cancer xenograft growth, probably as a consequence of ERbeta-mediated inhibition of cell-cycle pathways. Furthermore, this ERbeta-mediated cell cycle repression is dependent on functional ERE binding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602591     DOI: 10.1158/0008-5472.CAN-09-0506

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  91 in total

1.  Genetic variation in insulin pathway genes and distal colorectal adenoma risk.

Authors:  A Joan Levine; Ugonna Ihenacho; Won Lee; Jane C Figueiredo; David J Vandenberg; Christopher K Edlund; Brian D Davis; Mariana C Stern; Robert W Haile
Journal:  Int J Colorectal Dis       Date:  2012-05-30       Impact factor: 2.571

2.  Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells.

Authors:  Karin Edvardsson; Anders Ström; Philip Jonsson; Jan-Åke Gustafsson; Cecilia Williams
Journal:  Mol Endocrinol       Date:  2011-04-14

Review 3.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

4.  Therapeutic significance of estrogen receptor β agonists in gliomas.

Authors:  Gangadhara R Sareddy; Binoj C Nair; Vijay K Gonugunta; Quan-guang Zhang; Andrew Brenner; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2012-03-21       Impact factor: 6.261

5.  Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Authors:  L N Mathieu; N F Kanarek; H-L Tsai; C M Rudin; M V Brock
Journal:  Dis Esophagus       Date:  2013-10-07       Impact factor: 3.429

6.  Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer.

Authors:  Hakeemah Al-Nakhle; Philip A Burns; Michele Cummings; Andrew M Hanby; Thomas A Hughes; Sampoorna Satheesha; Abeer M Shaaban; Laura Smith; Valerie Speirs
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

7.  Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.

Authors:  Wan-Fu Wu; Laure Maneix; Jose Insunza; Ivan Nalvarte; Per Antonson; Juha Kere; Nancy Yiu-Lin Yu; Virpi Tohonen; Shintaro Katayama; Elisabet Einarsdottir; Kaarel Krjutskov; Yu-Bing Dai; Bo Huang; Wen Su; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

8.  Synthesis and biological evaluation of novel 5-chloro-N-(4-sulfamoylbenzyl) salicylamide derivatives as tubulin polymerization inhibitors.

Authors:  Alaaeldin M F Galal; Maha M Soltan; Esam R Ahmed; Atef G Hanna
Journal:  Medchemcomm       Date:  2018-07-26       Impact factor: 3.597

Review 9.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11

10.  Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Authors:  Giulia Pinton; Warren Thomas; Paolo Bellini; Arcangela Gabriella Manente; Roberto E Favoni; Brian J Harvey; Luciano Mutti; Laura Moro
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.